Radius Health (RDUS: Nasdaq) By Maxim Group ($60.00, June 22, 2015)
Radius Health’s stock has exceeded our prior price target of $50 quicker than we anticipated when we launched coverage in April. Additionally, stock rose another $10 through $60 on what we view as expected positive six-month data from the ACTIVExtend study.
We are downgrading Radius (ticker: RDUS) to Hold, from Buy, and removing our prior price target of $50….
